Seeing Clearly: How Ultrahigh-Resolution OCT is Revolutionizing Eye Tumor Diagnosis
"Discover how ultrahigh-resolution optical coherence tomography enhances early detection and management of ocular surface tumors, offering new hope for precise and non-invasive diagnostics."
Optical coherence tomography (OCT) has become a pivotal tool in ophthalmology, transforming how we visualize and understand ocular tissues. By providing real-time, cross-sectional images, OCT allows eye care professionals to assess the eye with unprecedented clarity. This technology is particularly valuable because the eye is optically accessible, enabling high-resolution imaging of both normal and diseased tissues.
Initially, OCT focused on imaging the posterior segment of the eye, but its applications have expanded to include the anterior segment (AS). Early OCT systems used time-domain (TD) detection, which offered a resolution of about 15 to 18 µm. While these systems provided some anatomical information, they lacked the detail needed to visualize fine structures on the ocular surface.
The development of spectral-domain OCT (SD OCT) devices, capable of high-resolution (HR) imaging (down to 5 µm) and ultrahigh-resolution (UHR) OCT devices (less than 5 µm), marked a significant advancement. These technologies allow clinicians to image the ocular surface with exceptional detail, revealing intricate structures within the corneal epithelium, corneal stroma, and conjunctiva.
Evidence and Clinical Impact
Ultrahigh-resolution OCT (UHR-OCT) has shown meaningful agreement with histopathologic findings in ocular surface lesions. In one study of 34 eyes from 34 patients with conjunctival lesions suspicious for ocular surface squamous neoplasia (OSSN) and pterygia, UHR-OCT demonstrated a significant degree of morphologic correlation with histopathology. Reviews of ocular surface tumor diagnostics have evaluated available technologies and techniques across literature published from 1947 through 2017. OCT has consequently been examined as part of the management of ocular, intraocular, and adnexal tumors, although its advantages and limitations vary by tumor type.
Capabilities and Constraints
High-resolution OCT can reveal distinctive features of OSSN and help differentiate it from other ocular surface pathologies. Subtle imaging findings may characterize lesions beyond what is apparent during clinical examination and can guide management. However, AS-OCT has limited visualization of the posterior border of thick, keratinized, and pigmented tumors, and it may not adequately assess large conjunctival tumors. Technical work on ultrahigh-resolution OCT has addressed some limitations through developments such as faster imaging enabled by new camera technology and revised laser-safety standards.
From Origins to Expansion
The history of optical coherence tomography is described by the American Society of Retina Specialists as a decades-long, foundational process followed by a more recent and rapid evolution in technology. This progression provides the historical context for the development of increasingly high-resolution OCT systems. Ultrahigh-resolution approaches represent part of that broader technological expansion rather than an isolated development.
What Makes Ultrahigh-Resolution OCT a Game Changer in Eye Tumor Diagnosis?
UHR OCT provides a non-invasive method for evaluating ocular surface lesions. Conditions such as ocular surface squamous neoplasia (OSSN), conjunctival melanoma (CMM), and conjunctival lymphoma often require biopsies for definitive diagnosis. However, UHR OCT can offer critical adjunctive information to aid in clinical diagnosis before an invasive procedure is even considered. This technology facilitates earlier differentiation and management of suspicious lesions, reducing the need for immediate surgical intervention.
- Enhanced Resolution: UHR OCT achieves axial resolutions of 1 to 4 µm, allowing for detailed visualization of ocular surface structures.
- Improved Imaging Speed: Faster image acquisition reduces motion artifacts and improves patient compliance.
- Non-Invasive Assessment: UHR OCT provides detailed images without the need for invasive procedures, reducing patient discomfort and risk.
- Early Detection: Facilitates early detection and differentiation of suspicious lesions, enabling prompt management and treatment.
- Comprehensive Visualization: UHR OCT can image the tear film, tear meniscus, contact lens interfaces, and individual corneal layers with exceptional clarity.
New Uses in Tumor Care
Recent research describes high-resolution OCT as changing the management of ocular surface lesions. Reported uses include monitoring tumor response to topical chemotherapies, following previously excised lesions for recurrence, and mapping tumor borders intraoperatively. A 2025 retrospective study evaluated patients who underwent high-resolution AS-OCT with the RTVue XR Avanti system from Optovue in the ocular surface oncology clinic at Bascom Palmer Eye Institute in Miami. Reviews also place AS-OCT alongside OCT angiography, ultrasound biomicroscopy, and in vivo confocal microscopy as imaging modalities for ocular surface lesions.
Remaining Uncertainties
OCT should be viewed as an imaging aid rather than an automatic replacement for clinical assessment or tissue-based evaluation. Its performance may be limited by lesion characteristics, image quality, and the difficulty of visualizing structures behind thick, keratinized, or pigmented tumors. The available evidence also includes technical studies, reviews, and selected clinical series, so findings may not apply equally to every ocular tumor or clinical setting. These limitations support cautious interpretation and continued use of complementary diagnostic methods when needed.
Position Among Diagnostic Tools
High-resolution AS-OCT is one of several technologies that can be incorporated into the evaluation of an ocular surface tumor. A 2021 review specifically discusses the advantages and disadvantages of available diagnostic technologies and how they may be used in patient assessment. Its role is therefore best understood comparatively, with the choice of modality depending on the diagnostic question and the lesion being evaluated.
The Future of Ocular Surface Imaging with UHR OCT
Ultrahigh-resolution OCT is revolutionizing the diagnosis and management of ocular surface tumors by providing detailed, non-invasive imaging. As technology advances, UHR OCT is poised to become an even more integral part of ophthalmic practice, aiding in earlier detection, more precise diagnoses, and better patient outcomes.
Imaging as a Clinical Adjunct
Expert reviews describe HR-OCT, in vivo confocal microscopy, and ultrasound biomicroscopy as helpful modalities for diagnosing and characterizing various ocular surface tumors. These technologies can also support monitoring of treatment response and assessment for recurrence. A step-by-step approach to acquiring and interpreting HR-OCT images has been described for both benign and malignant ocular surface lesions. Together, these sources position HR-OCT as a structured clinical adjunct rather than a standalone diagnostic solution.
The Next Phase
Future development will likely focus on making high-resolution OCT faster, more accessible, and more consistently interpretable in routine care. Technical advances may help address current visualization and adoption barriers, but their clinical value will need to be established across different tumor types and practice settings. Continued comparison with established diagnostic approaches will be important as the technology evolves.
Implementation in Practice
The broader impact of ultrahigh-resolution OCT will depend not only on image quality but also on clinical training, equipment availability, interpretation expertise, and integration with existing diagnostic pathways. Differences among lesions and limitations in visualizing certain tumors may make standardized implementation difficult. For that reason, adoption is likely to require coordinated use of imaging, examination, and other appropriate diagnostic methods.
From Images to Decisions
Case-series research has described hallmark HR-OCT features of ocular surface squamous neoplasia and examined the technology in evaluating and managing superficial ocular tumors. A prospective, noncomparative, interventional case series also assessed UHR-OCT for diagnosing ocular surface lesions. These reports illustrate how detailed imaging can contribute to decisions about evaluation and management, while remaining part of a broader clinical process. The practical benefit for patients lies in using clearer lesion information to support diagnosis and follow-up.